NATCO Pharma API unit in Mekaguda receives EIR from USFDA

The company received one observation in the Form-483

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D

Azelis acquires Azienda Chimica e Farmaceutica to expand presence in Italy

Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders

Nectar Lifesciences sell API and formulations business to Ceph Lifesciences for Rs. 1,270 Cr

Cadila Pharmaceuticals launches Bilacad Dex Syrup

A triple-action Formula for comprehensive respiratory relief

BASF opens new GMP Solution Center in US

BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America

Sai Life Sciences commences commercial operation of 2nd phase in Bidar

This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility

USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad

The company received one observation in the Form-483

USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad

The company received 1 (One) observation in the Form-483

Lubrizol's polymer excipient Apisolex featured in Phase I candidate

The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold